drugset / Trial / NCT04636957

A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)

NCT04636957

Phase 3 Unknown 600 enrolled Lee's Pharmaceutical Limited
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a phase Ⅲ, multicenter, randomized, evaluator-blinded, parallel-group, active-controlled study to assess the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution vs ciprofloxacin 0.3% otic solution in the treatment of AOE, and to assess the pharmacokinetic properties in 12 selected adult subjects. Eligible subjects will be randomized at 1:1 ration to either the treatment arm or control arm. All subject will receive 7 consecutive days of either ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution or ciprofloxacin 0.3% otic solution alone. The main objectives are to assess the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution in the treatment of AOE, and to assess the plasma concentration of ciprofloxacin and fluocinolone acetonide after multiple doses of test drug in 12 adult subjects, and evaluate the PK parameters.

Timeline

Start
2020-11
Primary completion
2021-12
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 0.75 mg Other
Subject Ciprofloxacin Small molecule 1.2 mg Other
Subject fluocinolone acetonide Small molecule 0.0625 mg Other

Indications